36
Views
12
CrossRef citations to date
0
Altmetric
CASE REPORT

New‐onset, debilitating arthritis in psoriasis patients receiving efalizumab

, &
Pages 353-354 | Received 03 Jul 2006, Accepted 06 Jul 2006, Published online: 12 Jul 2009
 

Abstract

Efalizumab is a humanized anti‐CD11a monoclonal IgG1 antibody approved for the treatment of moderate‐to‐severe plaque psoriasis. This case report describes two cases of new‐onset debilitating psoriatic arthritis in patients with plaque psoriasis on long‐standing efalizumab therapy, despite the fact that their skin disease was in remission. Although during the clinical trials, involving over 2700 study subjects, arthralgia was seen only at a rate of 1–2% higher than in those subjects receiving placebo, the cases presented here are interesting in that it appears that efalizumab treatment ‘uncoupled’ the psoriatic arthritic component from the cutaneous disease. It can be speculated that a possible mechanism for efalizumab‐induced psoriatic arthritis is related to the blockade of regulatory T cells from joint tissue.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.